AB Science Reports €10.4M H1 Loss, Launches Turnaround Plan
Event summary
- AB Science reports €10.4M operating loss for H1 2026, driven by €6.5M Research Tax Credit provision.
- Company raises €19.7M through private placements in 2026 to fund turnaround plan.
- Stéphane Ledermann appointed as new CEO, launching 'Relaunch AB Science' strategy.
- Clinical trial insurance of €25–39M secured for Phase 3 ALS study of masitinib.
- Patents granted for masitinib in progressive multiple sclerosis and metastatic prostate cancer.
The big picture
AB Science is undergoing a strategic pivot under new leadership, prioritizing quality assurance and clinical development for masitinib and AB8939. The €19.7M capital raise and clinical trial insurance mitigate some risk, but the company's ability to execute on its turnaround plan will be critical. The biotech sector's increasing focus on regulatory compliance and targeted therapies underscores the strategic importance of AB Science's initiatives.
What we're watching
- Clinical Timelines
- Whether AB Science can resume Phase 1 AML study in Q1 2027 and Phase 3 ALS study in Q4 2027 as planned.
- Financial Stability
- How the €8.9M cash position and €19.7M capital raise will sustain operations until next funding round.
- Regulatory Compliance
- The pace at which AB Science implements its new quality assurance system to meet Good Clinical Practice standards.
Related topics
